Biogen (BIIB) Profit After Tax (2009 - 2026)
Biogen (BIIB) posted quarterly Profit After Tax of $319.5 million for Q1 2026, up 32.85% year-over-year from $240.5 million in Q1 2025, and up 753.37% on a QoQ basis from -$48.9 million in Q4 2025.
Biogen (BIIB) Profit After Tax (2009 - 2026) Analysis & Trends
Biogen (BIIB) has reported Profit After Tax for 18 consecutive years, with $319.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 32.85% year-over-year to $319.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 7.26% YoY), while the FY2025 annual figure was $1.3 billion, down 20.79% from the prior year.
- Profit After Tax came in at $319.5 million for Q1 2026 at Biogen, up from -$48.9 million in the prior quarter.
- The five-year high for Profit After Tax was $1.1 billion in Q3 2022, with the low at -$68.3 million in Q3 2023.
- Average Profit After Tax over 5 years is $428.3 million, with a median of $388.5 million recorded in 2024.
- Across the five-year window, Profit After Tax jumped 2368.78% in 2022 and plunged 118.34% in 2025, its largest moves.
- Year by year, Profit After Tax stood at $465.1 million in 2022, then tumbled by 46.31% to $249.7 million in 2023, then rose by 6.81% to $266.7 million in 2024, then slumped by 118.34% to -$48.9 million in 2025, then surged by 753.37% to $319.5 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $319.5 million, -$48.9 million, and $466.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 3.08 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 319.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 319.50 Mn |
| Dec 31, 2025 | -48.90 Mn |
| Sep 30, 2025 | 466.50 Mn |
| Jun 30, 2025 | 634.80 Mn |
| Mar 31, 2025 | 240.50 Mn |
| Dec 31, 2024 | 266.70 Mn |
| Sep 30, 2024 | 388.50 Mn |
| Jun 30, 2024 | 583.60 Mn |
| Mar 31, 2024 | 393.40 Mn |
| Dec 31, 2023 | 249.70 Mn |
| Sep 30, 2023 | -68.30 Mn |
| Jun 30, 2023 | 591.60 Mn |
| Mar 31, 2023 | 387.60 Mn |
| Dec 31, 2022 | 465.10 Mn |
| Sep 30, 2022 | 1.13 Bn |
| Jun 30, 2022 | 1.06 Bn |
| Mar 31, 2022 | 218.50 Mn |
| Dec 31, 2021 | -20.50 Mn |
| Sep 30, 2021 | 329.20 Mn |
| Jun 30, 2021 | 448.50 Mn |